| scholarly article | Q13442814 |
| P356 | DOI | 10.1248/CPB.34.3025 |
| P953 | full work available at URL | https://www.jstage.jst.go.jp/article/cpb1958/34/7/34_7_3025/_pdf |
| P698 | PubMed publication ID | 3021351 |
| P7228 | access restriction status | open access | Q232932 |
| P2093 | author name string | Y Fujimoto | |
| N Ikekawa | |||
| K Kitabatake | |||
| A Morigiwa | |||
| P2860 | cites work | A Sensitive Fluorimetric Assay for Serum Angiotensin-con venrting Enzyme | Q40004952 |
| The biologically active constituents of Ganoderma lucidum (Fr.) Karst. Histamine release-inhibitory triterpenes | Q68942535 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Ganoderma lucidum | Q271098 |
| Ganoderic acid K | Q75059940 | ||
| (3S,5R,10S,13R,14R,17S)-17-[(E,2S)-7-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-3-ol | Q104916056 | ||
| (E,6S)-2-methyl-6-[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl]hept-2-enoic acid | Q104917084 | ||
| 7,12-Dihydroxy-3,11,15,23-tetraoxolanost-8-en-26-oic acid | Q105149850 | ||
| (2R,6S)-6-[(3S,5R,7S,10S,12S,13R,14R,17S)-12-acetyloxy-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid | Q105190286 | ||
| (5R,10S,13R,14R,17R)-17-[(E,2S)-7-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-3-one | Q105229149 | ||
| (E,6S)-2-methyl-6-[(5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3-oxo-1,2,5,6,12,15,16,17-octahydrocyclopenta[a]phenanthren-17-yl]hept-2-enal | Q105236520 | ||
| P6954 | online access status | open access | Q232932 |
| P304 | page(s) | 3025-3028 | |
| P577 | publication date | 1986-01-01 | |
| P1433 | published in | Chemical & Pharmaceutical Bulletin | Q13557315 |
| P1476 | title | Angiotensin converting enzyme-inhibitory triterpenes from Ganoderma lucidum | |
| P478 | volume | 34 |
| Q105314789 | 5′-Deoxy-5′-methylsulphinyladenosine, a platelet aggregation inhibitor from Ganoderma lucidum |
| Q35489947 | A Convenient RP-HPLC Method for Assay Bioactivities of Angiotensin I-Converting Enzyme Inhibitory Peptides |
| Q122745854 | A Review of Chemical Composition and Bioactivity Studies of the Most Promising Species of Ganoderma spp. |
| Q38264159 | A comprehensive review of the structure elucidation and biological activity of triterpenoids from Ganoderma spp. |
| Q113874136 | A concise review of mushrooms antiviral and immunomodulatory properties that may combat against COVID-19 |
| Q44029731 | A new lanostane-type triterpene from the fruiting bodies of Ganoderma lucidum |
| Q80157196 | ACE activity during the hypotension produced by standardized aqueous extract of Cecropia glaziovii Sneth: a comparative study to captopril effects in rats |
| Q80018264 | Analysis of triterpenoids in ganoderma lucidum using liquid chromatography coupled with electrospray ionization mass spectrometry |
| Q46985140 | Angiotensin converting enzyme inhibitory activity of amino acid esters of carbohydrates |
| Q44604831 | Angiotensin converting enzyme inhibitory phenylpropanoid glycosides from Clerodendron trichotomum |
| Q34484593 | Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum |
| Q51085165 | Antihypertensive activities of a solid-state culture of Taiwanofungus camphoratus (Chang-chih) in spontaneously hypertensive rats. |
| Q98177229 | Antimalarial lanostane triterpenoids from cultivated fruiting bodies of the basidiomycete Ganoderma sp |
| Q77727373 | Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics |
| Q43103149 | Antiplasmodial lanostanes from the Ganoderma lucidum mushroom |
| Q46868623 | Antiviral Terpenoid Constituents of Ganoderma pfeifferi |
| Q36537850 | Apoptotic and Immune Restoration Effects of Ganoderic Acids Define a New Prospective for Complementary Treatment of Cancer |
| Q43550146 | Assays for angiotensin converting enzyme inhibitory activity |
| Q38102733 | Bioactive natural constituents from food sources-potential use in hypertension prevention and treatment |
| Q104910991 | Biosynthesis of cryptoporic acids H and I in Ganoderma neo-japonicum |
| Q37741082 | Biotechnological production and application of ganoderic acids. |
| Q104389210 | Changes of the triterpenoid patterns during formation of the fruit body in Ganoderma lucidum |
| Q85403957 | Characterisation of a new antihypertensive angiotensin I-converting enzyme inhibitory peptide from Pleurotus cornucopiae |
| Q37385617 | Characterization of an antihypertensive angiotensin I-converting enzyme inhibitory peptide from the edible mushroom Hypsizygus marmoreus |
| Q91064250 | Chemical Components of Ganoderma |
| Q35958675 | Chromatographic and electrophoretic methods for Lingzhi pharmacologically active components |
| Q81499019 | Clinical outcomes of diabetic foot management with Circulat |
| Q42654428 | Cloning and characterization of a gene encoding HMG-CoA reductase from Ganoderma lucidum and its functional identification in yeast |
| Q103817478 | Comparative study on the strain-specific triterpenoid components of Ganoderma lucidum |
| Q100517725 | Coronaviruses and Nature's Pharmacy for the Relief of Coronavirus Disease 2019 |
| Q104397258 | Cryptoporic acids H and I, drimane sesquiterpenes from Ganoderma neo-japonicum and Cryptoporus volvatus |
| Q37791030 | Current progress in the study on biosynthesis and regulation of ganoderic acids |
| Q78287674 | Cytotoxic and anti-angiogenic effects of lanostane triterpenoids from Ganoderma lucidum |
| Q39951539 | Cytotoxic lanostanoid triterpenes from Ganoderma lucidum |
| Q78287215 | Cytotoxic triterpenoids from Ganoderma lucidum |
| Q42016161 | Determination of volatile aroma compounds of Ganoderma lucidum by gas chromatography mass spectrometry (HS-GC/MS). |
| Q34559076 | Effect of 26-oxygenosterols from Ganoderma lucidum and their activity as cholesterol synthesis inhibitors |
| Q44000382 | Effects of bulb of Fritillaria ussuriensis maxim. on angiotensin converting enzyme and vascular release of NO/cGMP in rats |
| Q33525742 | Effects of triterpenes from Ganoderma lucidum on protein expression profile of HeLa cells |
| Q91141521 | Eight new triterpenoids with inhibitory activity against HMG-CoA reductase from the medical mushroom Ganoderma leucocontextum collected in Tibetan plateau |
| Q83112482 | Electrospray tandem mass spectrometry of longipedlactone triterpenoids |
| Q47759845 | Ethnomedical information and in vitro screening for angiotensin-converting enzyme inhibition of plants utilized as traditional medicines in Gujarat, Rajasthan and Kerala (India). |
| Q41772648 | Evaluation of Selected Culinary-Medicinal Mushrooms for Antioxidant and ACE Inhibitory Activities |
| Q48515190 | Extract of white button mushroom affects skin healing and angiogenesis |
| Q78310471 | Extraction and isolation of ganoderic acid Σ from Ganoderma lucidum |
| Q44634737 | Fingerprint profiling of acid hydrolyzates of polysaccharides extracted from the fruiting bodies and spores of Lingzhi by high-performance thin-layer chromatography |
| Q92376388 | Ganoderal A effectively induces osteogenic differentiation of human amniotic mesenchymal stem cells via cross-talk between Wnt/β-catenin and BMP/SMAD signaling pathways |
| Q46529955 | Ganoderic acid Sz, a new lanostanoid from the mushroom Ganoderma lucidum |
| Q69648955 | Ganoderic acid and its derivatives as cholesterol synthesis inhibitors |
| Q104917086 | Ganoderic acid derivatives and ergosta-4,7,22-triene-3,6-dione from Ganoderma lucidum |
| Q34556748 | Ganoderma - a therapeutic fungal biofactory. |
| Q36944240 | Ganoderma lucidum and its pharmaceutically active compounds |
| Q24188117 | Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors |
| Q38066252 | Ganoderma lucidum: a potential for biotechnological production of anti-cancer and immunomodulatory drugs |
| Q34186251 | Ganoderol B: a potent α-glucosidase inhibitor isolated from the fruiting body of Ganoderma lucidum |
| Q79369691 | HPLC determination of four triterpenoids in rat urine after oral administration of total triterpenoids from Ganoderma lucidum |
| Q33269546 | HPLC method for the determination and pharmacokinetic studies of four triterpenoids in rat plasma after oral administration of Ganoderma lucidum extract |
| Q92132099 | Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety |
| Q73690602 | High-performance liquid chromatographic analysis for the characterization of triterpenoids from Ganoderma |
| Q42028315 | Hydrolyzates of silkworm pupae (Bombyx mori) protein is a new source of angiotensin I-converting enzyme inhibitory peptides (ACEIP). |
| Q44570855 | Hypotensive effect of butein via the inhibition of angiotensin converting enzyme |
| Q34623778 | Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). |
| Q34009232 | In vitro and in vivo anti-oxidant activity of hot water extract of basidiomycetes-X, newly identified edible fungus |
| Q58883772 | Inhibition of angiotensin converting enzyme (ACE) by flavonoids isolated fromAilanthus excelsa (Roxb) (Simaroubaceae) |
| Q57214686 | Inhibition of angiotensin converting enzyme by lithospermic acid B isolated from Radix Salviae miltiorrhiza Bunge |
| Q104917087 | Investigation of the biosynthesis of 3α-hydroxy triterpenoids, ganoderic acids T and S, by application of a feeding experiment using [1,2-13C2]acetate |
| Q47424047 | Isolation and characterization of a novel angiotensin I-converting enzyme inhibitory peptide derived from the edible mushroom Tricholoma giganteum |
| Q104916054 | Isolation of 3,4-seco-27-norlanostane triterpenoids from cultivated fruiting bodies of Ganoderma orbiforme |
| Q122877723 | Isolation of a novel peptide from silkworm pupae protein components and interaction characteristics to angiotensin I-converting enzyme |
| Q79658424 | Isolation of angiotensin converting enzyme (ACE) inhibiting triterpenes from Schinus molle |
| Q42830920 | Lanostane triterpenes from the fruiting bodies of Ganoderma lucidum and their inhibitory effects on adipocyte differentiation in 3T3-L1 Cells |
| Q39274255 | Lanostane triterpenoids and sterols from Antrodia camphorata |
| Q38762717 | Lanostane triterpenoids from Ganoderma curtisii and their NO production inhibitory activities of LPS-induced microglia |
| Q78287495 | Lanostane triterpenoids from Ganoderma luteomarginatum and their cytotoxicity against four human cancer cell lines |
| Q92121428 | Lanostane triterpenoids from cultivated fruiting bodies of the wood-rot basidiomycete Ganoderma casuarinicola |
| Q83205686 | Lanostane-type triterpenes from the sporoderm-broken spores of Ganoderma lucidum |
| Q59274396 | Lanostanoid Triterpenes fromGanodermalucidum |
| Q44706396 | Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganoderma lucidum and their inhibitory effects on Epstein-Barr virus activation |
| Q36371955 | Medicinal Benefits of the Mushroom Ganoderma |
| Q35646733 | Medicinal mushrooms: Towards a new horizon |
| Q46029409 | Metabolism and pharmacokinetics in rats of ganoderiol F, a highly cytotoxic and antitumor triterpene from Ganoderma lucidum. |
| Q38325833 | Microbial synthesis of metabolites with antihypertensive activity: aspects of fermentation derived inhibitors of angiotensin-converting enzyme (ACE). |
| Q38682539 | Misconstrued versatility of Ganoderma lucidum: a key player in multi-targeted cellular signaling. |
| Q42005413 | Molecular Mechanisms of Several Novel Dipeptides with Angiotensin-I-converting Enzyme Inhibitory Activity from In-silico Screening of Silkworm Pupae Protein |
| Q90537413 | Mushrooms: an emerging resource for therapeutic terpenoids |
| Q35192973 | Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions |
| Q78231479 | New Triterpenoids from the Fruiting Bodies ofGanoderma lucidumand Their Bioactivities |
| Q105004414 | New Unsaturated Lactones and a Meroterpenoid from Ganoderma lucidum |
| Q43927759 | New lanostanoids from the fungus Ganoderma concinna. |
| Q43865164 | New lanostanoids from the mushroom Ganoderma lucidum |
| Q44015148 | New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells |
| Q46286832 | One single standard substance for the simultaneous determination of 17 triterpenes in Ganoderma lingzhi and its related species using high-performance liquid chromatography |
| Q41876949 | Pharmacokinetics of ganoderic acids a and f after oral administration of ling zhi preparation in healthy male volunteers |
| Q36375306 | Pharmacological and anti-tumor activities of ganoderma spores processed by top-down approaches |
| Q58147794 | Phytotherapy for prostatism |
| Q35863325 | Potential anti-inflammatory, anti-adhesive, anti/estrogenic, and angiotensin-converting enzyme inhibitory activities of anthocyanins and their gut metabolites |
| Q91499652 | Preventive and Therapeutic Effect of Ganoderma (Lingzhi) on Renal Diseases and Clinical Applications |
| Q41833353 | Production of Antihypertensive Angiotensin I-Converting Enzyme Inhibitor from Malassezia pachydermatis G-14. |
| Q35875936 | Quality Difference Study of Six Varieties of Ganoderma lucidum with Different Origins |
| Q46985691 | Quantitative determination of six major triterpenoids in Ganoderma lucidum and related species by high performance liquid chromatography |
| Q56778742 | Reishi,Ganoderma lucidumandGanoderma tsugae: Bioactive substances and medicinal effects |
| Q46327970 | Secondary Metabolites from Higher Fungi. |
| Q38480267 | Secondary metabolites from Ganoderma |
| Q68538389 | Separation of oxygenated triterpenoids from Ganoderma lucidum by high-performance liquid chromatography |
| Q78442028 | Seven New Triterpenes from Ganoderma lucidum |
| Q92121673 | Steroid sulfatase inhibiting lanostane triterpenes - Structure activity relationship and in silico insights |
| Q34065475 | Structure-activity relationships of ganoderma acids from Ganoderma lucidum as aldose reductase inhibitors |
| Q35000258 | Structure-activity relationships of lanostane-type triterpenoids from Ganoderma lingzhi as α-glucosidase inhibitors |
| Q39233746 | Target proteins of ganoderic acid DM provides clues to various pharmacological mechanisms |
| Q38531512 | Tetracyclic triterpenoids in herbal medicines and their activities in diabetes and its complications. |
| Q34628017 | The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum |
| Q39684186 | The effects of ganoderma alcohols isolated from Ganoderma lucidum on the androgen receptor binding and the growth of LNCaP cells |
| Q24530116 | The pharmacological potential of mushrooms. |
| Q50058816 | The potential applications of mushrooms against some facets of atherosclerosis: A review |
| Q113184756 | Therapeutic potential of mushrooms in preventing and ameliorating hypertension |
| Q38148264 | Therapeutic properties of mushrooms in managing adverse effects in the metabolic syndrome |
| Q39572210 | Trends in protease inhibition |
| Q38702825 | Triterpenes and meroterpenes from Ganoderma lucidum with inhibitory activity against HMGs reductase, aldose reductase and α-glucosidase |
| Q105135538 | Triterpenes from Ganoderma lucidum |
| Q120074042 | Triterpenes from Ganoderma lucidum |
| Q74103011 | Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells |
| Q42538365 | Triterpenes from the spores of Ganoderma lucidum and their inhibitory activity against HIV-1 protease |
| Q67528977 | Triterpenoids |
| Q69566796 | Triterpenoids |
| Q104104049 | Triterpenoids from Antrodia cinnamomea |
| Q42809447 | Triterpenoids with neurotrophic activity from Ganoderma lucidum |
| Q78297187 | Two novel 3,4-seco-trinorlanostane triterpenoids isolated from Ganoderma fornicatum |
| Q64930205 | Two novel lanostane triterpenoids from Ganoderma sinense. |
| Q120281823 | Utilization of Shrimp By-Products by Bioconversion with Medical Fungi for Angiotensin I-Converting Enzyme Inhibitor and Antioxidant |
| Q39221864 | Wild Mushrooms in Nepal: Some Potential Candidates as Antioxidant and ACE-Inhibition Sources |
Search more.